Next Generation

Immuno-Oncology Therapeutics

Viatonix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline  of drug candidates that target different  TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.


The Viatonix team has created the HERA-ligand technology platform for the development of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology.


Our lead immuno-oncology candidate asunercept is in clinical development for the treatment of a variety of solid tumors and malignant hematological diseases. It has demonstrated statistically significant efficacy in a controlled phase II proof-of-concept trial in recurrent glioblastoma. Patients with a certain biomarker experienced the greatest benefit from treatment with asunercept. Apogenix is developing a companion diagnostic test based on this biomarker, so asunercept can be used as a personalized therapy.


July 23, 2019
Excellent Preclinical Efficacy Data of Viatonix’ HERA-GITRL Published in Journal for ImmunoTherapy of Cancer

May 7, 2019
Viatonix to Present at Four Upcoming International Conferences

Get in Touch at Any Time

Germany Head Office

Im Neuenheimer Feld 585
 69120 Heidelberg

Phone : +49 302 202 7148

Email :

Get in Touch at Any Time

United States of America

 Georgia World Congress Center, Atlanta, GA, 

United States of America

Phone : +1 223 344 5566

Email :

India _ Asia Pacific

Millennium Avenue, Whitefield, Palm Meadows, Whitefield, Bengaluru, Karnataka 560066

Phone : +91 0866 6714 542 

Email :